Immunomedics, Inc.  

(Public, NASDAQ:IMMU)   Watch this stock  
Find more results for IMMU
11.02
-0.37 (-3.25%)
After Hours: 11.02 0.00 (0.00%)
Nov 22, 4:46PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.93 - 11.51
52 week 3.01 - 14.48
Open 11.25
Vol / Avg. 1.55M/2.94M
Mkt cap 1.68B
P/E     -
Div/yield     -
EPS -2.24
Shares 152.02M
Beta 1.55
Inst. own 80%
Nov 9, 2017
Q1 2018 Immunomedics Inc Earnings Call - Webcast
Sep 12, 2017
Immunomedics Inc at Rodman & Renshaw Global Investment Conference
Sep 11, 2017
Immunomedics Inc at Morgan Stanley Healthcare Conference
Sep 6, 2017
Immunomedics Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin -17199.70% -4958.07%
Operating margin -5011.36% -2560.44%
EBITD margin - -2530.57%
Return on average assets -301.55% -139.64%
Return on average equity - -
Employees 138 -
CDP Score - -

Address

300 the American Rd
MORRIS PLAINS, NJ 07950-2460
United States - Map
+1-973-6058200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Officers and directors

Behzad Aghazadeh Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Michael R. Garone Chief Financial Officer, Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
David M. Goldenberg Chief Scientific Officer, Chief Patent Officer, Director
Age: 79
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brendan Delaney Chief Commercial Officer
Bio & Compensation  - Reuters
Cynthia L. Sullivan Director
Age: 61
Bio & Compensation  - Reuters
Scott A. Canute Independent Director
Age: 57
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 82
Bio & Compensation  - Reuters
Khalid Islam Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Brian A. Markison Lead Independent Director
Age: 58
Bio & Compensation  - Reuters